GLP-1s and addiction risks drop
35:11–38:38 · 207s
Shani summarizes a VA cohort: starting GLP-1s links to fewer new SUD diagnoses and fewer serious SUD outcomes versus SGLT2s, translating to tangible patient-level differences.
35:11–38:38 · 207s
Shani summarizes a VA cohort: starting GLP-1s links to fewer new SUD diagnoses and fewer serious SUD outcomes versus SGLT2s, translating to tangible patient-level differences.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.